✦ LIBER ✦

Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy

✍ Scribed by Cesare Gridelli; Amin M. Haiderali; Mark W. Russo; Linda M. Blackburn; Konstantinos Lykopoulos

Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 277 KB
Volume: 18
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-009-0766-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The cardiovascular safety of high-dose i

The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy

✍ James Carmichael; AdrianL. Harris 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 185 KB

Epoetin alfa increases hemoglobin levels

Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy

✍ Matti S. Aapro; David C. Dale; Michael Blasi; Brenda Sarokhan; Fawzia Ahmed; Ric 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 161 KB

Epoetin alfa corrects anemia and improve

Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy

✍ Timothy J. Littlewood; Johan Nortier; Bernardo Rapoport; Marek Pawlicki; Gilbert 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB

Anemia, a commonly occurring morbidity in patients with cancer, often leads to diminished quality of life (QOL). Numerous clinical trials have shown that epoetin alfa treatment improves hematologic and QOL variables in cancer patients. The clinical trial analysis reported here was performed to asses

Development of Quality of Life Questionn

Development of Quality of Life Questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy

✍ Minoru Kurihara; Hiroyuki Shimizu; Koji Tsuboi; Kunihiko Kobayashi; Minoru Murak 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Epoetin alfa improves quality of life in

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy

✍ Paul J. Pockros; Mitchell L. Shiffman; Eugene R. Schiff; Mark S. Sulkowski; Zoba 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Anemia and decreased health-related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining R

Phase 2 trial results with the novel neu

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

✍ Wichit Arpornwirat; Istvan Albert; Vincent L. Hansen; Jeremey Levin; Rajesh R. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 1 views